Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (January 2025)
10 slides from Imugene's shareholder meeting presentation, Jan 22, 2025
Slide 1: Extraordinary General Meeting
For personal use only EXTRAORDINARY GENERAL MEETING Wednesday, 22 January 2025 1 Release authorised by the Managing Director and Chief Executive Officer Imugene Limited
Slide 2: Company Overview
Company Overview Imugene is a clinical-stage immuno-oncology company developing a range of novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors For personal use only 3 PLATFORM TECHNOLOGIES In cell therapy, oncolytic virus & innovative combin
Slide 3: EGM – Market Update: Financial Summary
EGM – Market Update Financial For personal use only Convertible bond and warrant facility with CVI Investments Inc. Up to an additional $26 million Summary for up to $46 million, with $20 million immediately following if warrants are exercised over today’s EGM the next 5 years $11.7 million R&D reba
Slide 4: 67% Complete Response Rates Observed in Phase 1b Cohort B
67% Complete Response Rates Observed in Phase 1b Cohort B Evaluable patients: Evaluable Evaluable Cohort A+B patients: patients: (N=9) Cohort A (N=6) Cohort B (N=3) For personal use only Cohort A Overall 6 Response Rate % 4 (44%) 2 (33%) 2 (67%) Patients Complete 3 (33%) 1 (17%) 2 (67%) Lymphodeplet
Slide 5: Phase 1 MAST Trial − Encouraging Early Signals
Phase 1 MAST Trial − Encouraging Early Signals Patients1 • >40 patients have been dosed and evaluated (at least their first scan at day 42) For personal use only Disease Control So Far • Nearly half of the evaluable patients (48%) have remained on treatment for >3 months • 3 patients have remained o
Slide 6: Imugene Has Initiated The OASIS Phase 1 Open Label Trial
Imugene Has Initiated The OASIS Phase 1 Open Label Trial with CD19 Virus and Blinatumomab For personal use only Combination treatment for solid cancers + onCARlytics CD19 Bispecific CD19 virus antibody Recruiting up to 40 patients First patient dosed July 2023 at City of Hope Multiple trial sites in
Slide 7: onCARlytics: Extensive Possibilities
onCARlytics: Extensive Possibilities Solid tumors, which lack CD19, represent Combination Opportunities ~90% For personal use only Company Product Target Indications First FDA Approval of the cancer market. CD19 Auto CAR T B-ALL, DLBCL 2017 onCARlytics can become the preferred partner for opening th
Slide 8: 2024 Highlights And Expected Upcoming Key Catalysts
2024 Highlights And Expected Upcoming Key Catalysts 2024 2025 Program 1H 2H 1H 2H For personal use only • 3 CRs in Phase 1b • Preliminary early DLBCL • First patient dosed in AUS DLBCL trial • Expansion into Phase 1b data update additional blood cancers azer-cel (Phase 1b Expansion Cohorts) • Orphan
Slide 9: Transformative Cancer Therapies To Watch In 2025
Transformative Cancer Therapies To Watch In 2025 POSSIBILITIES AND • Encouraging results in three novel programs, with expansions into new indications • Addressing unmet patient needs, with significant available markets and growth potential PROMISE FOR 2025 For personal use only • Extensive safety d
Slide 10: For personal use only
ASX : IMU For personal use only shareholderenquiries@imugene.com imugene.com 10